PDCD1 and melanoma: In addition, Wang et al.56 have shown that, in colorectal carcinoma and melanoma, depletion of METTL3 and METTL14 enhances the response to anti-PD-1 blockade therapy through stabilizing Stat1 and Irf1 mRNA.